Initial Experience of Atezolizumab Plus Bevacizumab for Advanced Hepatocellular Carcinoma in Clinical Practice

Teiji Kuzuya; Naoto Kawabe; Senju Hashimoto; Ryoji Miyahara; Takuji Nakano; Kazunori Nakaoka; Hiroyuki Tanaka; Yohei Miyachi; Arisa Mii; Yoshinao Tanahashi; Yutaro Kato; Atsushi Sugioka; Yoshiki Hirooka

doi:10.21873/cdp.10012

Initial Experience of Atezolizumab Plus Bevacizumab for Advanced Hepatocellular Carcinoma in Clinical Practice

Teiji Kuzuya, Naoto Kawabe, Senju Hashimoto, Ryoji Miyahara, Takuji Nakano, Kazunori Nakaoka, Hiroyuki Tanaka, Yohei Miyachi, Arisa Mii, Yoshinao Tanahashi, Yutaro Kato, Atsushi Sugioka, Yoshiki Hirooka

Research output: Contribution to journal › Article › peer-review

17 Citations (Scopus)

Abstract

Background/Aim: The aim of this study was to investigate the outcomes of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma (HCC), including those with disease refractory to lenvatinib, in clinical practice. Patients and Methods: Of 34 patients treated with atezolizumab plus bevacizumab, a total of 23, including 16 with lenvatinib failure, were enrolled in this retrospective study. The adverse events, changes in liver function and antitumor responses at 6 weeks after starting therapy were evaluated. Results: The incidence of grade 3 adverse events was low, at 13.0%. Albumin–bilirubin scores did not worsen at 3 and 6 weeks compared to baseline. The objective response rate and disease control rate at 6 weeks were 17.4% and 78.3% according to Response Evaluation Criteria in Solid Tumors (RECIST), and 30.4% and 78.3% according to modified RECIST, respectively. Conclusion: Our results suggest that atezolizumab plus bevacizumab might have potential therapeutic safety and efficacy in patients with advanced HCC, including those with disease refractory to lenvatinib. Further studies are needed to confirm the outcomes of atezolizumab plus bevacizumab after lenvatinib failure.

Original language	English
Pages (from-to)	83-88
Number of pages	6
Journal	Cancer Diagnosis and Prognosis
Volume	1
Issue number	2
DOIs	https://doi.org/10.21873/cdp.10012
Publication status	Published - 2021

All Science Journal Classification (ASJC) codes

Cancer Research
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.21873/cdp.10012

Cite this

@article{d6f77f62127346b4b0043305dbbc4dde,

title = "Initial Experience of Atezolizumab Plus Bevacizumab for Advanced Hepatocellular Carcinoma in Clinical Practice",

abstract = "Background/Aim: The aim of this study was to investigate the outcomes of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma (HCC), including those with disease refractory to lenvatinib, in clinical practice. Patients and Methods: Of 34 patients treated with atezolizumab plus bevacizumab, a total of 23, including 16 with lenvatinib failure, were enrolled in this retrospective study. The adverse events, changes in liver function and antitumor responses at 6 weeks after starting therapy were evaluated. Results: The incidence of grade 3 adverse events was low, at 13.0%. Albumin–bilirubin scores did not worsen at 3 and 6 weeks compared to baseline. The objective response rate and disease control rate at 6 weeks were 17.4% and 78.3% according to Response Evaluation Criteria in Solid Tumors (RECIST), and 30.4% and 78.3% according to modified RECIST, respectively. Conclusion: Our results suggest that atezolizumab plus bevacizumab might have potential therapeutic safety and efficacy in patients with advanced HCC, including those with disease refractory to lenvatinib. Further studies are needed to confirm the outcomes of atezolizumab plus bevacizumab after lenvatinib failure.",

keywords = "Atezolizumab, bevacizumab, hepatocellular carcinoma, lenvatinib, liver function",

author = "Teiji Kuzuya and Naoto Kawabe and Senju Hashimoto and Ryoji Miyahara and Takuji Nakano and Kazunori Nakaoka and Hiroyuki Tanaka and Yohei Miyachi and Arisa Mii and Yoshinao Tanahashi and Yutaro Kato and Atsushi Sugioka and Yoshiki Hirooka",

note = "Publisher Copyright: {\textcopyright} 2021 International Institute of Anticancer Research.",

year = "2021",

doi = "10.21873/cdp.10012",

language = "English",

volume = "1",

pages = "83--88",

journal = "Cancer Diagnosis and Prognosis",

issn = "2732-7787",

publisher = "International Institute of Anticancer Research",

number = "2",

}

TY - JOUR

T1 - Initial Experience of Atezolizumab Plus Bevacizumab for Advanced Hepatocellular Carcinoma in Clinical Practice

AU - Kuzuya, Teiji

AU - Kawabe, Naoto

AU - Hashimoto, Senju

AU - Miyahara, Ryoji

AU - Nakano, Takuji

AU - Nakaoka, Kazunori

AU - Tanaka, Hiroyuki

AU - Miyachi, Yohei

AU - Mii, Arisa

AU - Tanahashi, Yoshinao

AU - Kato, Yutaro

AU - Sugioka, Atsushi

AU - Hirooka, Yoshiki

PY - 2021

Y1 - 2021

N2 - Background/Aim: The aim of this study was to investigate the outcomes of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma (HCC), including those with disease refractory to lenvatinib, in clinical practice. Patients and Methods: Of 34 patients treated with atezolizumab plus bevacizumab, a total of 23, including 16 with lenvatinib failure, were enrolled in this retrospective study. The adverse events, changes in liver function and antitumor responses at 6 weeks after starting therapy were evaluated. Results: The incidence of grade 3 adverse events was low, at 13.0%. Albumin–bilirubin scores did not worsen at 3 and 6 weeks compared to baseline. The objective response rate and disease control rate at 6 weeks were 17.4% and 78.3% according to Response Evaluation Criteria in Solid Tumors (RECIST), and 30.4% and 78.3% according to modified RECIST, respectively. Conclusion: Our results suggest that atezolizumab plus bevacizumab might have potential therapeutic safety and efficacy in patients with advanced HCC, including those with disease refractory to lenvatinib. Further studies are needed to confirm the outcomes of atezolizumab plus bevacizumab after lenvatinib failure.

AB - Background/Aim: The aim of this study was to investigate the outcomes of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma (HCC), including those with disease refractory to lenvatinib, in clinical practice. Patients and Methods: Of 34 patients treated with atezolizumab plus bevacizumab, a total of 23, including 16 with lenvatinib failure, were enrolled in this retrospective study. The adverse events, changes in liver function and antitumor responses at 6 weeks after starting therapy were evaluated. Results: The incidence of grade 3 adverse events was low, at 13.0%. Albumin–bilirubin scores did not worsen at 3 and 6 weeks compared to baseline. The objective response rate and disease control rate at 6 weeks were 17.4% and 78.3% according to Response Evaluation Criteria in Solid Tumors (RECIST), and 30.4% and 78.3% according to modified RECIST, respectively. Conclusion: Our results suggest that atezolizumab plus bevacizumab might have potential therapeutic safety and efficacy in patients with advanced HCC, including those with disease refractory to lenvatinib. Further studies are needed to confirm the outcomes of atezolizumab plus bevacizumab after lenvatinib failure.

KW - Atezolizumab

KW - bevacizumab

KW - hepatocellular carcinoma

KW - lenvatinib

KW - liver function

UR - http://www.scopus.com/inward/record.url?scp=85111711088&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85111711088&partnerID=8YFLogxK

U2 - 10.21873/cdp.10012

DO - 10.21873/cdp.10012

M3 - Article

AN - SCOPUS:85111711088

SN - 2732-7787

VL - 1

SP - 83

EP - 88

JO - Cancer Diagnosis and Prognosis

JF - Cancer Diagnosis and Prognosis

IS - 2

ER -

Initial Experience of Atezolizumab Plus Bevacizumab for Advanced Hepatocellular Carcinoma in Clinical Practice

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this